For laboratory research use only.
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is among the first synthetic growth hormone–releasing peptides. Long before ghrelin was purified as an endogenous ligand, hexapeptide GHRPs were already forcing endocrinology to recognize a GH-release pathway that was not simply GHRH in disguise.
From early hexapeptides to a receptor class
Mid-1980s work showed that GHRP-6 and related hexapeptides could stimulate GH release through mechanisms distinct from GHRH (Bowers et al., 1984). Follow-on studies mapped pituitary and hypothalamic responses and helped define what later became the ghrelin receptor (GHS-R1a) pharmacology field (GHRP pathway literature). That chronology explains why GHRP-6 remains a historical reference ligand even when newer analogs dominate modern catalogs.
Comparative endocrine profile
When Raun and colleagues profiled ipamorelin, GHRP-6 served as a benchmark for GH potency and efficacy in rat pituitary cells and in animals. In swine, GHRP-6 (like GHRP-2) increased ACTH and cortisol under conditions where ipamorelin did not, despite comparable GH-release efficacy themes (Raun et al., 1998). Separately, GHRP-6 is widely discussed for pronounced ghrelin-like effects on appetite-related signaling. Feeding-behavior models sometimes choose it for that reason; other designs treat the same signal as unwanted variance.
Choosing GHRP-6 on purpose
Use GHRP-6 when the scientific question needs continuity with early GHRP literature, a hexapeptide chemotype, or a strong ghrelin-mimetic comparator. Do not treat it as a stand-in for GHRP-2, hexarelin, ipamorelin, or any GHRH analog. Different ligands answer different questions even when they share a receptor family.
Catalog reference materials in this receptor family include GHRP-6 5mg, Hexarelin 2mg, and ipamorelin nasal spray — each for laboratory research use only.
Sources
- Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the rat. (Endocrinology, 1985, PMID 4029086)
- Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men. (Endocrinol Jpn, 1991, PMID 1915110)
- Ipamorelin, the first selective growth hormone secretagogue. (Eur J Endocrinol, 1998, PMID 9849822)